Analyst Ratings for Beam Therapeutics
Beam Therapeutics Questions & Answers
The latest price target for Beam Therapeutics (NASDAQ: BEAM) was reported by Cantor Fitzgerald on August 12, 2022. The analyst firm set a price target for $4.00 expecting BEAM to fall to within 12 months (a possible -94.21% downside). 100 analyst firms have reported ratings in the last year.
The latest analyst rating for Beam Therapeutics (NASDAQ: BEAM) was provided by Cantor Fitzgerald, and Beam Therapeutics initiated their overweight rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Beam Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Beam Therapeutics was filed on August 12, 2022 so you should expect the next rating to be made available sometime around August 12, 2023.
While ratings are subjective and will change, the latest Beam Therapeutics (BEAM) rating was a initiated with a price target of $0.00 to $4.00. The current price Beam Therapeutics (BEAM) is trading at is $69.08, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.